AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20077149 — intervention group
Group type: COMPARATOR
Intervention: Assessment data provided to clinicians
Number of subjects: 173
Study 20077149 — intervention group
Group type: COMPARATOR
Intervention: Organizational support for family services
Number of subjects: 173
Study 17907110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar (0.5 or 1 mg/day)
Number of subjects: 0
Study 17907110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16287387 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (5 to 45 min)
Number of subjects: 76
Study 16287387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 12180212 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine system for fracture diagnosis by OMFS doctors
Number of subjects: 16
Study 12180212 — intervention group
Group type: COMPARATOR
Intervention: Plain radiography
Number of subjects: 16
Study 12180212 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine system
Number of subjects: 16
Study 10616948 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Unilateral ECT (RUL) with age-based dosing (5.0 mC per year)
Number of subjects: 80
Study 10616948 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Unilateral ECT (RUL) with fixed high dose (378 mC)
Number of subjects: 80
Study 10616948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (BF) with age-based dosing
Number of subjects: 80
Study 10616948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-titration method
Number of subjects: 80
Study 7543328 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser prostatectomy
Number of subjects: 0
Study 2754281 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram/day alfacalcidol for 9.67 months
Number of subjects: 24
Study 2754281 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group observed for 9.92 months
Number of subjects: 24
Study 9967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 17
Study 9967 — intervention group
Group type: EXPERIMENTAL
Intervention: Medazepam (15 mg)
Number of subjects: 17
Study 9967 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 17
Study 9967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31447130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks for up to 172 weeks
Number of subjects: 340
Study 28719592 — intervention group
Group type: EXPERIMENTAL
Intervention: TL quadruple therapy (esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.)
Number of subjects: 102
Study 28719592 — intervention group
Group type: COMPARATOR
Intervention: AL triple therapy (esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.)
Number of subjects: 102
Study 28719592 — intervention group
Group type: EXPERIMENTAL
Intervention: TL quadruple therapy
Number of subjects: 102
Study 28719592 — intervention group
Group type: COMPARATOR
Intervention: AL triple therapy
Number of subjects: 102
Study 25315022 — intervention group
Group type: EXPERIMENTAL
Intervention: LED therapy (625 nm, 4 J/cm²) with Unna's boot
Number of subjects: 17
Study 25315022 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with Unna's boot (Control)
Number of subjects: 17
Study 23742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal Actions (RA)
Number of subjects: 24
Study 23742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Superset (SS)
Number of subjects: 24
Study 23742915 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Set (MS)
Number of subjects: 24
Study 21284982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary inorganic nitrate supplementation
Number of subjects: 0
Study 19485990 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN)
Number of subjects: 350
Study 19485990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 16816054 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated estrogens (n = 20)
Number of subjects: 60
Study 16816054 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin titrated to 2,400 mg/d (n = 20)
Number of subjects: 60
Study 16816054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 60
Study 12777548 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting education program (intervention group)
Number of subjects: 286
Study 12777548 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting education program (intervention group) with 30+ contacts
Number of subjects: 286
Study 12777548 — intervention group
Group type: COMPARATOR
Intervention: Standard social services (control group)
Number of subjects: 286
Study 11235451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aseptic, non‐touch technique
Number of subjects: 79
Study 11235451 — intervention group
Group type: COMPARATOR
Intervention: Sterile technique
Number of subjects: 79
Study 9101193 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 48933
Number of subjects: 10
Study 9101193 — intervention group
Group type: COMPARATOR
Intervention: Saline (vehicle)
Number of subjects: 10
Study 7906659 — intervention group
Group type: EXPERIMENTAL
Intervention: azelastine nasal spray (0.14 mg/nostril administered twice daily)
Number of subjects: 30
Study 7906659 — intervention group
Group type: COMPARATOR
Intervention: loratidine tablets (10 mg once daily)
Number of subjects: 30
Study 3106208 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% amino-acid solution with 6% carbohydrates
Number of subjects: 20
Study 3106208 — intervention group
Group type: COMPARATOR
Intervention: Water and electrolytes
Number of subjects: 20
Study 29316405 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-zinc-calcium-vitamin D co-supplements
Number of subjects: 60
Study 29316405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27542731 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 314
Study 27542731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 25470975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengzhanhua injection and Xiongqin injection combined with Xuesaitong
Number of subjects: 140
Study 25470975 — intervention group
Group type: COMPARATOR
Intervention: Xuesaitong
Number of subjects: 140
Study 22721656 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3075
Study 22721656 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3075
Study 20457688 — intervention group
Group type: EXPERIMENTAL
Intervention: Research study offering improved outcomes
Number of subjects: 4685
Study 20457688 — intervention group
Group type: COMPARATOR
Intervention: Research study offering only reductions in risk for adverse effects
Number of subjects: 4685
Study 20457688 — intervention group
Group type: COMPARATOR
Intervention: Research study scenarios with the same risks but less benefit
Number of subjects: 4685
Study 20457688 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental sociodemographics and numeracy
Number of subjects: 4685
Study 18511528 — intervention group
Group type: EXPERIMENTAL
Intervention: COM
Number of subjects: 46
Study 18511528 — intervention group
Group type: EXPERIMENTAL
Intervention: END
Number of subjects: 46
Study 18511528 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 46
Study 16198843 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (176 to 185 mg flavanols)
Number of subjects: 11
Study 16198843 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (NO-synthase inhibitor)
Number of subjects: 11
Study 16198843 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 11
Study 15195981 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster Grandparent Program
Number of subjects: 52
Study 15195981 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 52
Study 10569666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol with aspirin
Number of subjects: 50
Study 10569666 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 50
Study 8753934 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body weight)
Number of subjects: 0
Study 8753934 — intervention group
Group type: COMPARATOR
Intervention: Lactose (control)
Number of subjects: 0
Study 1877264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 185
Study 1877264 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 185
Study 6211147 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐killed sonicated suspension of malassezia ovalis
Number of subjects: 20
Study 6211147 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐killed sonicated suspension of Staphylococcus epidermidis
Number of subjects: 20
Study 6211147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and histological lesions consistent with psoriasis
Number of subjects: 20
Study 31784435 — intervention group
Group type: EXPERIMENTAL
Intervention: Mikono Safi intervention (multi-modal school-based WASH intervention)
Number of subjects: 116
Study 31784435 — intervention group
Group type: EXPERIMENTAL
Intervention: Mikono Safi intervention
Number of subjects: 116
Study 29850709 — intervention group
Group type: EXPERIMENTAL
Intervention: Açaí beverage (325 mL twice per day for 12 weeks)
Number of subjects: 37
Study 29850709 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (325 mL twice per day for 12 weeks)
Number of subjects: 37
Study 27565010 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) injection, 1ml of 0.5% solution
Number of subjects: 50
Study 27565010 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 50
Study 25192389 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 1037
Study 22828021 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive antiemetic medication
Number of subjects: 1151
Study 22828021 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of significant risk factors
Number of subjects: 1151
Study 22828021 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive antiemetic medication administration
Number of subjects: 1151
Study 19944870 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recovery telehealth intervention (6 weeks)
Number of subjects: 55
Study 19944870 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study 19944870 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 55
Study 17486385 — intervention group
Group type: EXPERIMENTAL
Intervention: Six hours of classroom instruction and workshop time with professors of theater.
Number of subjects: 20
Study 17486385 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 20
Study 14711543 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microM FF-MAS in 0.2% ethanol
Number of subjects: 210
Study 14711543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microM FF-MAS in 0.2% ethanol
Number of subjects: 210
Study 14711543 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microM FF-MAS in 0.2% ethanol
Number of subjects: 210
Study 14711543 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ethanol
Number of subjects: 210
Study 14711543 — intervention group
Group type: COMPARATOR
Intervention: Water for injection (control)
Number of subjects: 210
Study 11403366 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg/day)
Number of subjects: 10
Study 11403366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9693999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 20
Study 9693999 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) infusion
Number of subjects: 20
Study 9693999 — intervention group
Group type: COMPARATOR
Intervention: 2.5% saline infusion
Number of subjects: 20
Study 8164080 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory percussion (AP) examination
Number of subjects: 293
Study 8164080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 293
Study 3276864 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (20 mg/kg/d at 8-hour intervals for 10 to 14 days)
Number of subjects: 42
Study 3276864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, gentamicin, and clindamycin
Number of subjects: 42
Study 3276864 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin and gentamicin (control group)
Number of subjects: 42
Study 29420324 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative mitomycin C (MMC) injection (0.1 mL of 0.15 mg/mL MMC) followed by pterygium excision and conjunctival autograft (CAG)
Number of subjects: 108
Study 29420324 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative local application of MMC (0.2 mg/mL for 2 min) over the medial rectus tendon followed by pterygium excision and CAG
Number of subjects: 108
Study 27281308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 744
Study 27281308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 744
Study 24731467 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing 70 mg isoflavone daily for one year
Number of subjects: 75
Study 24731467 — intervention group
Group type: COMPARATOR
Intervention: Control group without soy protein intake
Number of subjects: 75
Study 21962771 — intervention group
Group type: COMPARATOR
Intervention: Oral intervention (O)
Number of subjects: 75
Study 21962771 — intervention group
Group type: COMPARATOR
Intervention: Tactile/Kinesthetic intervention (T/K)
Number of subjects: 75
Study 21962771 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention (O+T/K)
Number of subjects: 75
Study 21962771 — intervention group
Group type: COMPARATOR
Intervention: All three interventions (O, T/K, O+T/K)
Number of subjects: 75
Study 21962771 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 75
Study 21911634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaspirin NSAIDs
Number of subjects: 126928
Study 21911634 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and acetaminophen
Number of subjects: 126928
Study 18187944 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI 100
Number of subjects: 1469
Study 18187944 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI 90 to <100
Number of subjects: 1469
Study 18187944 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI 75 to <90
Number of subjects: 1469
Study 18187944 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI 50 to <75
Number of subjects: 1469
Study 18187944 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI 25 to <50
Number of subjects: 1469
Study 18187944 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI <25
Number of subjects: 1469
Study 16638934 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent imatinib and induction cycle 2 (INDII)
Number of subjects: 92
Study 16638934 — intervention group
Group type: COMPARATOR
Intervention: Alternating imatinib schedule
Number of subjects: 92
Study 16638934 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent imatinib and chemotherapy
Number of subjects: 92
Study 16638934 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 92
Study 14719287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufei Keli (Chinese drug granules for invigorating the lung)
Number of subjects: 62
Study 14719287 — intervention group
Group type: COMPARATOR
Intervention: Yupingfeng Keli (control group)
Number of subjects: 62
Study 10771454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg day‐1 in two divided daily doses for 8 days
Number of subjects: 19
Study 10771454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8658373 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiorphan 1 mg (in 2 ml) followed by ANP 5 mg
Number of subjects: 6
Study 8658373 — intervention group
Group type: COMPARATOR
Intervention: ANP 5 mg alone
Number of subjects: 6
Study 8658373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) followed by ANP 5 mg
Number of subjects: 6
Study 8658373 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 5 mg
Number of subjects: 6
Study 1804493 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 104353‐Z2 (800 micrograms via aerosol)
Number of subjects: 12
Study 1804493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1804493 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 104353‐Z2
Number of subjects: 12
Study 6095658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 0
Study 6095658 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 0
Study 6095658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30739640 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2.0-mm AO locking reconstruction plate
Number of subjects: 80
Study 30739640 — intervention group
Group type: COMPARATOR
Intervention: Two conventional miniplates
Number of subjects: 80
Study 30552161 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab preinduction (2 cycles)
Number of subjects: 30
Study 30552161 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction I (6 cycles obinutuzumab and venetoclax)
Number of subjects: 30
Study 30552161 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction II (6 cycles venetoclax)
Number of subjects: 30
Study 30552161 — intervention group
Group type: COMPARATOR
Intervention: Maintenance with 12 additional cycles of venetoclax irrespective of MRD (group A)
Number of subjects: 30
Study 30552161 — intervention group
Group type: COMPARATOR
Intervention: MRD guided venetoclax maintenance with a maximum of 12 cycles (group B)
Number of subjects: 30
Study 27074873 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 60
Study 27074873 — intervention group
Group type: COMPARATOR
Intervention: Poor effort group
Number of subjects: 60
Study 24930624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1090
Study 24930624 — intervention group
Group type: COMPARATOR
Intervention: IFN‐α/Placebo
Number of subjects: 1090
Study 22964703 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpantenolo (pantothenic acid derivative), administered intravenously during the second and third post-operative day.
Number of subjects: 60
Study 22964703 — intervention group
Group type: COMPARATOR
Intervention: Physiological solution (Placebo), administered to the control group.
Number of subjects: 60
Study 22964703 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthetic treatment group.
Number of subjects: 60
Study 22964703 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridural anesthetic treatment group.
Number of subjects: 60
Study 20645106 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (25 mg)
Number of subjects: 67
Study 20645106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 20645106 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CVR
Number of subjects: 67
Study 20645106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CVR
Number of subjects: 67
Study 17949673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (LUCENTIS)
Number of subjects: 0
Study 17949673 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin (VISUDYNE) photodynamic therapy (PDT)
Number of subjects: 0
Study 15827560 — intervention group
Group type: EXPERIMENTAL
Intervention: 80:20 CLA isomer blend (1.76 g CLA)
Number of subjects: 55
Study 15827560 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (2 g CLA)
Number of subjects: 55
Study 15827560 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid (2 g linoleic acid)
Number of subjects: 55
Study 12107508 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol eyedrops
Number of subjects: 8
Study 12107508 — intervention group
Group type: COMPARATOR
Intervention: Intravenous timolol (0.2 mg)
Number of subjects: 8
Study 12107508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular timolol (0.2 mg)
Number of subjects: 8
Study 12107508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic timolol
Number of subjects: 8
Study 12107508 — intervention group
Group type: COMPARATOR
Intervention: Intravenous timolol
Number of subjects: 8
Study 9661686 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative blood deposit status (autologous blood collection)
Number of subjects: 2590
Study 9661686 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion(s) received
Number of subjects: 2590
Study 9661686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean number of units collected per patient
Number of subjects: 2590
Study 9661686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean number of unused autologous units per 100 patients
Number of subjects: 2590
Study 9661686 — intervention group
Group type: EXPERIMENTAL
Intervention: Deposited blood requiring allogeneic units
Number of subjects: 2590
Study 9661686 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 2590
Study 9661686 — intervention group
Group type: EXPERIMENTAL
Intervention: Last hematocrits
Number of subjects: 2590
Study 7697521 — intervention group
Group type: EXPERIMENTAL
Intervention: Francisella tularensis live vaccine strain (LVS)
Number of subjects: 0
Study 2653095 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 1.5% with adrenaline
Number of subjects: 40
Study 2653095 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl (100 micrograms in saline 10 ml)
Number of subjects: 40
Study 331052 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadyl acetate (80 mg)
Number of subjects: 60
Study 331052 — intervention group
Group type: COMPARATOR
Intervention: Methadone (50 mg)
Number of subjects: 60
Study 331052 — intervention group
Group type: COMPARATOR
Intervention: Methadone (100 mg)
Number of subjects: 60